MN · State regulatory reference
Minnesota.
Moderate
Minnesota permits telehealth practice of medicine under Minn. Stat. § 147.033, which expressly allows a physician-patient relationship to be established via telehealth and holds it to the in-person standard of care, with 'telehealth' defined in Minn. Stat. § 62A.673 as real-time two-way interactive audio-and-visual communication (audio-only permitted for limited scheduled/crisis services through July 1, 2027). Compounding under Minn. Rule 6800.3300 mandates USP <795> (non-sterile) and <797> (sterile), placing sterile injectables such as compounded GLP-1s under standard board oversight. No documented Minnesota board enforcement targeting peptides or GLP-1 compounding was found.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Minn. Stat. § 147.033 allows the physician-patient relationship to be established through telehealth with no prior in-person requirement; § 62A.673 defines telehealth as real-time two-way audio-visual, with audio-only allowed for limited scheduled/crisis services until July 1, 2027.
Compounding
Minn. Rule 6800.3300 requires USP <795> for non-sterile and <797> for sterile compounding; the Board applies limited enforcement discretion only for low-risk activities (e.g., flavoring), and sterile injectable compounding is held to full USP <797>.
Sources